Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 2/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122490 | 0.79 | SLC40A1 (0.49) | P2RX7MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL2117300 | 0.79 | MAPT (0.46) | P2RX7MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL2116719 | 0.79 | P2RX7 (0.39) | P2RX7MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL2119955 | 0.79 | KMT2A (0.43) | P2RX7MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL2119284 | 0.77 | TRIM24 (0.45) | MEN1KMT2APOLBHSD17B10MAPT | |
| SCHEMBL2119403 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2117745 | 0.75 | ALDH1A1 (0.39) | MEN1KMT2APOLBMAPTTDP1 | |
| SCHEMBL2119327 | 0.75 | MEN1 (0.46) | MEN1KMT2APOLBHSD17B10MAPT | |
| SCHEMBL2121542 | 0.74 | ALDH1A1 (0.41) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2119339 | 0.74 | ACLY (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | P2RX7 1426/4885MEN1 3143/4885KMT2A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.